The ingredient contains a minimum of 550 mg/g natural triglyceride DHA (docosahexaenoic acid), allowing manufacturers to achieve equivalent dosages of DHA in smaller product formats.
Photo © iStockphoto.com/Rinelle
Royal DSM (Heerlan, The Netherlands) has launched its new, higher potency life’sDHA SF55-O200DS oil for maternal and early life nutrition solutions. The ingredient contains a minimum of 550 mg/g natural triglyceride DHA (docosahexaenoic acid), allowing manufacturers to achieve equivalent dosages of DHA in smaller product formats.
DMS’s life’sDHA SF55-O200DS oil is produced from Schizochytrium algae, offering a sustainable, plant-based alternative to fish oil, and is contaminant-free, kosher, and halal. The product, which can be consumed in a convenient single dose is both aimed at women who are planning to conceive, are pregnant, breastfeeding, or non-breastfeeding post-natal mothers, as well as infants.
“Convenience, quality, and safety are key drivers of consumer purchasing in the maternal and early life nutrition markets, with mothers and expectant moms looking for easy-to-swallow dietary supplements and safe infant nutrition products made with trusted, science-backed ingredients,” said Brent MacDonald, director global marketing and business development, Nutritional Lipids at DSM, in a press release. “We carefully formulated life’sDHA SF55-O200DS to help manufacturers develop high-quality, reliable DHA solutions that will give pregnant women and moms peace of mind and that will shape healthier futures worldwide.”
Nutritional Outlook's Women in Nutraceuticals Roundtable: The Future of Women's Health Research
July 19th 2024Watch "The Future of Women's Health Research," a roundtable discussion presented by Nutritional Outlook in partnership with Women in Nutraceuticals. This roundtable is supplement to a recent article commissioned by WIN and published by Nutritional Outlook, titled “Taking Initiative: Can the WHI’s model help the nutraceutical industry answer questions the study didn’t even ask?”